Einzeltreffer — DigiBib

Purpose: The accuracy of positron emission tomography (PET)/CT with [(11)C]choline for the detection of prostate cancer is not well established. We assessed the dependence of [(11)C]choline maximum standardized uptake values (SUV(max)) in the prostate gland on cell malignancy, prostate-specific antigen (PSA) levels, Gleason score, tumour stage and anti-androgenic hormonal therapy.

Methods: In this prospective study, PET/CT with [(11)C]choline was performed in 19 prostate cancer patients who subsequently underwent prostatectomy with histologic sextant analysis (group A) and in six prostate cancer patients before and after anti-androgenic hormonal therapy (bicalutamide 150 mg/day; median treatment of 4 months; group B).

Results: In group A, based on a sextant analysis with a [(11)C]choline SUV(max) cutoff of 2.5 (as derived from a receiver-operating characteristic analysis), PET/CT showed sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 72, 43, 64, 51 and 60%, respectively. In the patient-by-patient analysis, no significant correlation was detected between SUV(max) and PSA levels, Gleason score or pathological stage. On the contrary, a significant (P < 0.05) negative correlation was detected between SUV(max) and anti-androgenic therapy both in univariate (r (2) = 0.24) and multivariate (r (2) = 0.48) analyses. Prostate [(11)C]choline uptake after bicalutamide therapy significantly (P < 0.05) decreased compared to baseline (6.4 +/- 4.6 and 11.8 +/- 5.3, respectively; group B).

Conclusion: PET/CT with [(11)C]choline is not suitable for the initial diagnosis and local staging of prostate cancer. PET/CT with [(11)C]choline could be used to monitor the response to anti-androgenic therapy.

Titel:	[(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy.
Autor/in / Beteiligte Person:	Giovacchini, G ; Picchio, M ; Coradeschi, E ; Scattoni, V ; Bettinardi, V ; Cozzarini, C ; Freschi, M ; Fazio, F ; Messa, C
Link:	Full Text Finder (Volltext)
Zeitschrift:	European journal of nuclear medicine and molecular imaging, Jg. 35 (2008-06-01), Heft 6, S. 1065-73
Veröffentlichung:	Berlin : Springer-Verlag Berlin, 2002-, 2008
Medientyp:	academicJournal
ISSN:	1619-7070 (print)
DOI:	10.1007/s00259-008-0716-2
Schlagwort:	Aged Antineoplastic Agents therapeutic use Carbon Radioisotopes pharmacokinetics Humans Male Middle Aged Neoplasm Staging Radiopharmaceuticals pharmacokinetics Statistics as Topic Treatment Outcome Androgen Antagonists therapeutic use Choline pharmacokinetics Positron-Emission Tomography methods Prostate-Specific Antigen blood Prostatic Neoplasms diagnosis Prostatic Neoplasms drug therapy Prostatic Neoplasms metabolism Tomography, X-Ray Computed methods
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Eur J Nucl Med Mol Imaging] 2008 Jun; Vol. 35 (6), pp. 1065-73. <i>Date of Electronic Publication: </i>2008 Jan 16. MeSH Terms: Prostatic Neoplasms* / diagnosis ; Prostatic Neoplasms* / drug therapy ; Prostatic Neoplasms* / metabolism ; Androgen Antagonists / therapeutic use ; Choline / pharmacokinetics ; Positron-Emission Tomography / methods ; Prostate-Specific Antigen / blood ; Tomography, X-Ray Computed / *methods ; Aged ; Antineoplastic Agents / therapeutic use ; Carbon Radioisotopes / pharmacokinetics ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Radiopharmaceuticals / pharmacokinetics ; Statistics as Topic ; Treatment Outcome Comments: Comment in: Eur J Nucl Med Mol Imaging. 2008 Sep;35(9):1740-1. (PMID: 18566818) References: J Steroid Biochem Mol Biol. 1998 Apr;65(1-6):191-8. (PMID: 9699873) ; Nucl Med Commun. 2001 Sep;22(9):963-9. (PMID: 11505204) ; Annu Rev Nutr. 1981;1:95-121. (PMID: 6764726) ; Urol Int. 2005;74(3):214-20. (PMID: 15812206) ; Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):668-73. (PMID: 15765234) ; Recent Results Cancer Res. 2007;175:211-37. (PMID: 17432562) ; Nucl Med Biol. 2004 Oct;31(7):859-65. (PMID: 15464387) ; J Urol. 1993 Jul;150(1):135-41. (PMID: 7685422) ; Radiology. 2001 Feb;218(2):365-74. (PMID: 11161148) ; J Urol. 2004 Jun;171(6 Pt 1):2260-4. (PMID: 15126798) ; J Urol. 2005 Jan;173(1):252-5. (PMID: 15592091) ; Eur J Nucl Med. 2000 Sep;27(9):1415-9. (PMID: 11007527) ; Eur J Nucl Med Mol Imaging. 2007 Jan;34(1):45-53. (PMID: 16932935) ; J Urol. 1991 Feb;145(2):313-8. (PMID: 1703240) ; J Urol. 2003 Apr;169(4):1337-40. (PMID: 12629355) ; J Urol. 2006 Sep;176(3):954-60; discussion 960. (PMID: 16890665) ; Urology. 1994 May;43(5):649-59. (PMID: 7513108) ; J Nucl Med. 2005 Oct;46(10):1642-9. (PMID: 16204714) ; Radiology. 1996 Mar;198(3):795-805. (PMID: 8628874) ; Magn Reson Med. 2001 Jul;46(1):49-57. (PMID: 11443710) ; J Nucl Med. 2003 Mar;44(3):331-5. (PMID: 12620996) ; Nucl Med Biol. 2002 Nov;29(8):783-90. (PMID: 12453586) ; J Nucl Med. 2006 Feb;47(2):262-9. (PMID: 16455632) ; Biochem Biophys Res Commun. 2002 Aug 23;296(3):580-3. (PMID: 12176020) ; Eur J Nucl Med. 2000 Jan;27(1):25-32. (PMID: 10654143) ; Radiology. 2005 May;235(2):623-8. (PMID: 15858102) ; J Nucl Med. 1998 Jun;39(6):990-5. (PMID: 9627331) ; Cancer. 1997 Jul 15;80(2):237-41. (PMID: 9217036) ; J Nucl Med. 2006 Aug;47(8):1249-54. (PMID: 16883001) ; Cancer Res. 2001 May 1;61(9):3599-603. (PMID: 11325827) ; Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):317-24. (PMID: 14628097) ; Cancer. 2006 Feb 15;106(4):775-82. (PMID: 16400637) ; Radiother Oncol. 2005 Jul;76(1):4-10. (PMID: 16145740) ; Eur Urol. 1993;24(4):461-5. (PMID: 8287886) ; J Nucl Med. 2004 Mar;45(3):519-25. (PMID: 15001697) ; Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):742-8. (PMID: 16052370) ; Eur Urol. 2002 Jul;42(1):18-23. (PMID: 12121724) ; Nucl Med Biol. 2006 Nov;33(8):977-84. (PMID: 17127170) ; Cancer Res. 1998 Jul 15;58(14):3009-14. (PMID: 9679964) ; Nucl Med Biol. 2004 Oct;31(7):867-74. (PMID: 15464388) ; Curr Opin Urol. 2007 May;17(3):188-93. (PMID: 17414517) ; Cancer. 2002 Sep 15;95(6):1215-9. (PMID: 12216087) Substance Nomenclature: 0 (Androgen Antagonists) ; 0 (Antineoplastic Agents) ; 0 (Carbon Radioisotopes) ; 0 (Radiopharmaceuticals) ; EC 3.4.21.77 (Prostate-Specific Antigen) ; N91BDP6H0X (Choline) Entry Date(s): Date Created: 20080118 Date Completed: 20081014 Latest Revision: 20220311 Update Code: 20231215

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

[(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy.